Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study

被引:62
作者
Liu, Chaoqun [1 ]
Zhang, Yuan [2 ]
Ding, Ding [1 ]
Li, Xinrui [1 ]
Yang, Yunou [1 ]
Li, Qing [1 ]
Zheng, Yuanzhu [1 ]
Wang, Dongliang [1 ]
Ling, Wenhua [1 ]
机构
[1] Sun Yat Sen Univ, Guangdong Prov Key Lab Food Nutr & Hlth, Dept Nutr, Sch Publ Hlth, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangzhou Mil Command Peoples Liberat Army, Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
High-density lipoprotein; Cholesterol efflux capacity; Coronary artery disease; All-cause mortality; Cardiovascular mortality; HIGH-DENSITY-LIPOPROTEIN; HDL-CHOLESTEROL; HIGH-RISK; ASSOCIATION; GUIDELINES; MANAGEMENT; ATHEROSCLEROSIS; HYPERGLYCEMIA; REGRESSION; EVENTS;
D O I
10.1016/j.atherosclerosis.2015.10.111
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although diminished cholesterol efflux capacity is positively related with prevalent coronary artery disease, its prognostic value for incident cardiovascular events remains a topic of debate. This work aims to investigate the association between cholesterol efflux capacity and all-cause and cardiovascular mortality in patients with coronary artery disease. Methods and Results: We measured cholesterol efflux capacity at baseline in 1737 patients with coronary artery disease from the Guangdong Coronary Artery Disease Cohort. During 6645 person-years of follow-up, 166 deaths were registered, 122 of which were caused by cardiovascular diseases. After multivariate adjustment for factors related to cardiovascular diseases, the hazard ratios of cholesterol efflux capacity in the fourth quartile compared with those in the bottom quartile were 0.24 (95% confidence intervals 0.13-0.44) for all-cause mortality (P < 0.001), and 0.17 (95% confidence intervals 0.08-0.39) for cardiovascular mortality (P < 0.001). Adding cholesterol efflux capacity to a model containing traditional cardiovascular risk factors significantly increases its discriminatory power and predictive ability for all-cause (area under receiver operating characteristic curve 0.79 versus 0.76, P = 0.001; net reclassification improvement 14.5%, P = 0.001; integrated discrimination improvement 0.016, P < 0.001) and cardiovascular (area under receiver operating characteristic curve 0.81 versus 0.78, P = 0.001; net reclassification improvement 18.4%, P < 0.001; integrated discrimination improvement 0.015, P < 0.001) death, respectively. Conclusions: Cholesterol efflux capacity may serve as an independent measure for predicting all-cause and cardiovascular mortality in patients with coronary artery disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:116 / 124
页数:9
相关论文
共 48 条
[1]   LIPIDS HDL cholesterol is not HDL-don't judge the book by its cover [J].
Arsenault, Benoit J. ;
Despres, Jean-Pierre .
NATURE REVIEWS CARDIOLOGY, 2012, 9 (10) :557-558
[2]   ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Eagle, KA ;
Faxon, DP ;
Fuster, V ;
Gardner, TJ ;
Gregoratos, G ;
Russell, RO ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :970-1056
[3]   Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis [J].
Briel, Matthias ;
Ferreira-Gonzalez, Ignacio ;
You, John J. ;
Karanicolas, Paul J. ;
Akl, Elie A. ;
Wu, Ping ;
Blechacz, Boris ;
Bassler, Dirk ;
Wei, Xinge ;
Sharman, Asheer ;
Whitt, Irene ;
da Silva, Suzana Alves ;
Khalid, Zahira ;
Nordmann, Alain J. ;
Zhou, Qi ;
Walter, Stephen D. ;
Vale, Noah ;
Bhatnagar, Neera ;
O'Regan, Christopher ;
Mills, Edward J. ;
Bucher, Heiner C. ;
Montori, Victor M. ;
Guyatt, Gordon H. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338
[4]   Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management [J].
Chapman, M. John ;
Ginsberg, Henry N. ;
Amarenco, Pierre ;
Andreotti, Felicita ;
Boren, Jan ;
Catapano, Alberico L. ;
Descamps, Olivier S. ;
Fisher, Edward ;
Kovanen, Petri T. ;
Kuivenhoven, Jan Albert ;
Lesnik, Philippe ;
Masana, Luis ;
Nordestgaard, Borge G. ;
Ray, Kausik K. ;
Reiner, Zeljko ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Tybjaerg-Hansen, Anne ;
Watts, Gerald F. .
EUROPEAN HEART JOURNAL, 2011, 32 (11) :1345-1361
[5]  
CLIFTON PM, 1985, J LIPID RES, V26, P1389
[6]  
Collins R, 2004, LANCET, V363, P757
[7]   Beyond high-density lipoprotein cholesterol levels - Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches [J].
deGoma, Emil M. ;
deGoma, Rolando L. ;
Rader, Daniel J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (23) :2199-2211
[8]  
Ding D., 2014, BIOMED RES INT, V2014
[9]   Serum Levels of Monocyte Chemoattractant Protein-1 and All-Cause and Cardiovascular Mortality among Patients with Coronary Artery Disease [J].
Ding, Ding ;
Su, Dongfang ;
Li, Xinrui ;
Li, Zhongxia ;
Wang, Yujie ;
Qiu, Jian ;
Lin, Puqing ;
Zhang, Yuan ;
Guo, Pi ;
Xia, Min ;
Li, Dan ;
Yang, Yan ;
Hu, Gang ;
Ling, Wenhua .
PLOS ONE, 2015, 10 (03)
[10]   Hyperglycemia and Mortality Among Patients With Coronary Artery Disease [J].
Ding, Ding ;
Qiu, Jian ;
Li, Xinrui ;
Li, Dan ;
Xia, Min ;
Li, Zhongxia ;
Su, Dongfang ;
Wang, Yujie ;
Zhang, Yuan ;
Zhang, Jinxia ;
Lv, Xiaofei ;
Xiao, Yunjun ;
Hu, Gang ;
Ling, Wenhua .
DIABETES CARE, 2014, 37 (02) :546-554